Next Article in Journal
Global Research Trends in the Latarjet Procedure: A Bibliometric and Visualized Study
Previous Article in Journal
Assessment of Different Techniques for Adhesive Cementation of All-Ceramic Systems
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Medicina
Volume 58
Issue 8
10.3390/medicina58081007
medicina-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Evaluation of Remdesivir for Mildly to Moderately Ill Patients with COVID-19: A Single-Arm, Single-Center, Retrospective Study

by
Motoyasu Miyazaki
1,2,*,
Ryoko Yanagida
2,
Akio Nakashima
1,2,
Koichi Matsuo
1,2,
Norihiro Moriwaki
3,
Masanobu Uchiyama
2,
Yota Yamada
2,
Hitomi Hirata
2,
Hisako Kushima
4,
Yoshiaki Kinoshita
4,
Hiroshi Ishii
4 and
Osamu Imakyure
1,2
1
Department of Pharmaceutical and Health Care Management, Faculty of Pharmaceutical Sciences, Fukuoka University, Fukuoka 814-0180, Japan
2
Department of Pharmacy, Fukuoka University Chikushi Hospital, Chikushino 818-8502, Japan
3
Department of Pharmacy, Fukuoka University Hospital, Fukuoka 814-0180, Japan
4
Department of Respiratory Medicine, Fukuoka University Chikushi Hospital, Chikushino 818-8502, Japan
*
Author to whom correspondence should be addressed.
Medicina 2022, 58(8), 1007; https://doi.org/10.3390/medicina58081007
Submission received: 18 June 2022 / Revised: 24 July 2022 / Accepted: 25 July 2022 / Published: 27 July 2022
(This article belongs to the Section Infectious Disease)
Browse Figures
Versions Notes

Abstract

Background and Objectives: Remdesivir (RDV) is the first antiviral agent approved in Japan for the treatment of coronavirus disease 2019 (COVID-19). The aim of our study was to assess the efficacy and safety of RDV treatment in mildly to moderately ill patients with COVID-19. Materials and Methods: A single-center, retrospective study was performed in Fukuoka University Chikushi Hospital. Patients admitted to our hospital from June to October 2021 for RDV treatment against COVID-19 were enrolled. The primary end point was clinical status on days 10 and 14, using a 6-point ordinal scale ranging from death (category 6) to discharge (category 1). Adverse events were assessed and graded using the Japanese version of Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Results: In total, 47 COVID-19 patients receiving RDV treatment were assessed during the study period. Thirty-four (72.3%) out of 47 patients required oxygen therapy. Out of these 34 patients, 30 (88.2%) showed a 2-point clinical improvement on day 14 after RDV was initiated. Serum alanine aminotransferase levels were elevated in three patients (6.4%) (CTCAE Grade 3) and neutropenia was detected in one patient (2.1%) out of the 47 patients. Conclusions: RDV may be highly effective, with good safety profiles, in patients with COVID-19 requiring oxygen therapy.
Keywords: coronavirus; COVID-19; remdesivir; oxygen therapy coronavirus; COVID-19; remdesivir; oxygen therapy

Share and Cite

MDPI and ACS Style

Miyazaki, M.; Yanagida, R.; Nakashima, A.; Matsuo, K.; Moriwaki, N.; Uchiyama, M.; Yamada, Y.; Hirata, H.; Kushima, H.; Kinoshita, Y.; et al. Evaluation of Remdesivir for Mildly to Moderately Ill Patients with COVID-19: A Single-Arm, Single-Center, Retrospective Study. Medicina 2022, 58, 1007. https://doi.org/10.3390/medicina58081007

AMA Style

Miyazaki M, Yanagida R, Nakashima A, Matsuo K, Moriwaki N, Uchiyama M, Yamada Y, Hirata H, Kushima H, Kinoshita Y, et al. Evaluation of Remdesivir for Mildly to Moderately Ill Patients with COVID-19: A Single-Arm, Single-Center, Retrospective Study. Medicina. 2022; 58(8):1007. https://doi.org/10.3390/medicina58081007

Chicago/Turabian Style

Miyazaki, Motoyasu, Ryoko Yanagida, Akio Nakashima, Koichi Matsuo, Norihiro Moriwaki, Masanobu Uchiyama, Yota Yamada, Hitomi Hirata, Hisako Kushima, Yoshiaki Kinoshita, and et al. 2022. "Evaluation of Remdesivir for Mildly to Moderately Ill Patients with COVID-19: A Single-Arm, Single-Center, Retrospective Study" Medicina 58, no. 8: 1007. https://doi.org/10.3390/medicina58081007

APA Style

Miyazaki, M., Yanagida, R., Nakashima, A., Matsuo, K., Moriwaki, N., Uchiyama, M., Yamada, Y., Hirata, H., Kushima, H., Kinoshita, Y., Ishii, H., & Imakyure, O. (2022). Evaluation of Remdesivir for Mildly to Moderately Ill Patients with COVID-19: A Single-Arm, Single-Center, Retrospective Study. Medicina, 58(8), 1007. https://doi.org/10.3390/medicina58081007

Article Metrics

Back to TopTop